BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

MAINZ, Germany, March 28, 2023 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) today announced that it has entered into a new share repurchase program (the “Program”), pursuant to which the Company may purchase American Depositary Shares, each representing one ordinary share (“ADS”), of the Company in the amount of up to $0.5 billion during the remainder of 2023. BioNTech expects to use all or a portion of the repurchased ADSs and the ADSs held in treasury to satisfy upcoming settlement obligations under the Company's share-based payment arrangements.

BioNTech Announces New ADS Repurchase Program

BioNTech announced its Q422 and FY22 earnings today, and also provided FY23 guidance. Revenues were ~$18.7bn, thanks to its share of revenues from sales of the Comirnaty COVID vaccine it co-developed with Pfizer. Net profit was >$10bn.

BioNTech FY22 Earnings Review - 5 Questions Answered After Today's Results

BioNTech SE (NASDAQ:BNTX ) Q4 2022 Results Conference Call March 27, 2023 8:00 AM ET Company Participants Michael Horowicz - IR and Strategy Ugur Sahin - CEO and Co-Founder Özlem Türeci - Chief Medical Officer and Co-Founder Jens Holstein - CFO Ryan Richardson - Chief Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Daina Graybosch - SVB Securities Matthew Harrison - Morgan Stanley Yaron Werber - Cowen Jessica Fye - JP Morgan Michael Horowicz Good morning and afternoon. Thank you for joining us today for BioNTech's fourth quarter and full year 2022 earnings call.

BioNTech SE (BNTX) Q4 2022 Earnings Call Transcript

BioNTech's guidance points to a big drop in revenue this year. The company is using its cash reserves to fund 24 clinical trials.

Why Shares of BioNTech Slumped Monday

The shares initially fell by 6.4% to an intraday low of $119.98 a share before recovering most of those losses in late morning trading.

BioNTech shares slip on gloomy Covid vaccine sales outlook

BioNTech (NASDAQ: BNTX) got a substantial boost from the pandemic and its mRNA vaccine, developed with Pfizer (NYSE: PFE). The stock has seen a substantial correction since then due to slowing COVID sales, but the bottom is in.

BioNTech Is Ripe For A Rebound In 2023

BioNTech said Monday it expects roughly $5.4 billion in sales of its Covid shot this year, missing views and leading BNTX stock to tumble. The post BioNTech Stock Crumbles After 2023 Outlook Misses By Almost $3 Billion appeared first on Investor's Business Daily.

BioNTech Stock Crumbles After 2023 Outlook Misses By Almost $3 Billion

The German biotech that partnered with Pfizer to develop a Covid-19 vaccine expects fewer vaccinations and lowered levels of boosting this year.

BioNTech Stock Is Falling. Blame the Covid Vaccine Outlook.

The U.S.-listed shares of BioNTech SE BNTX, -0.92% fell 2.7% in premarket expectations, as profit and revenue beat expectations but fell from a year ago due to lower demand for COVID-19 vaccines, and indicated demand would fall further. Net income fell to EUR2.28 billion ($2.45 billion), or EUR9.26 a share, from EUR#.17 billion, or EUR12.18 a share, in the year-ago period.

BioNTech stock falls as earnings beat expectations, but show falling demand for COVID-19 vaccines

Conference call and webcast scheduled for March 27 at 8:00 am ET (2:00 pm CET)

BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

CGI Group

Micron Technology

QUALCOMM

Biogen

Moderna

Sociedad Quimica Y Minera De Chile

Although blue-chip stocks often carry a reputation for being lumbering giants that might not kill your portfolio but certainly won't do it any favors, specific stalwarts can get the business done. In other words, these enterprises hit the sweet spot: they're tied to well-established businesses that also offer double-digit (percentage) upside potential, as determined by Wall Street analysts.

7 Blue-Chip Stocks Sitting in the Sweet Spot

Carnival

In early trading Thursday, the Dow Jones industrials were up 0.25%, the S&P 500 up 0.62% and the Nasdaq up 1.21%.

Earnings Previews: BioNTech, Carnival

BioNTech SE BNTX, -1.76% will pay $200 million to the privately held OncoC4 Inc. as part of a deal to develop and commercialize OncoC4's monoclonal antibody treatment that is being tested in several cancers. OncoC4 is also eligible for milestone payments and royalties, though the terms were not disclosed in the news release.

BioNTech inks deal with OncoC4 to develop cancer treatments

MAINZ, Germany and ROCKVILLE, Maryland, USA, March 20, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel biologicals for cancer treatment, today announced that they have entered into an exclusive worldwide license and collaboration agreement to develop and commercialize OncoC4's next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392, as monotherapy or combination therapy in various cancer indications. The transaction is expected to close in the first half of 2023, subject to customary closing conditions and regulatory clearances.

BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications

AmerisourceBergen

Cardinal Health

Valero Energy

Andersons

Offerpad Solutions

Performance Food Group

While time in the market generally beats out timing the market, it's understandable that some investors may want to hold off on looking for stocks to buy. After all, equities continue to digest the sudden failure of a handful of financial institutions.

7 Stocks Set to Soar When the Market Recovers

Pfizer

The Food and Drug Administration on Tuesday said children between the ages of 6 months and 5 years old can now get a booster dose of BioNTech BNTX and Pfizer's PFE COVID-19 bivalent vaccine. The third shot should come no sooner than two months after the primary series of three shots.

FDA updates authorization of BioNTech, Pfizer's bivalent booster for young children

MAINZ, Germany , March 13, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the full year and fourth quarter 2022 on Monday, March 27th, 2023. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the fourth quarter and full year 2022.

BioNTech to Report Full Year and Fourth Quarter 2022 Financial Results and Operational Update on March 27, 2023

Inexpensive valuations are good opportunities to purchase long-term investments. BioNTech has a bunch of therapeutic vaccine candidates in the works.

Wall Street Thinks These 2 Undervalued Stocks Have Exceptional Growth Potential

Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) said has developed a new platform of potential anti-cancer messenger RNA (mRNA) therapeutics, expanding the company's portfolio to five in-house programmes. The initiative consists of four pre-clinical putative treatments focusing on the company's MDK, or Midkine, target - a protein that plays a key role in the development and progression of cancer.

Roquefort develops a fifth programme using a technology pioneer by Moderna and BioNTech

Their latest COVID-19 vaccine is up for approvals in pediatric populations. In the first half, the COVID-19/flu shot combo has an early look.

Buy BioNTech For Multiple Catalysts In 2023

JERUSALEM, Israel, March 1, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech”, “the Company”) announced that the Company and the Weizmann Institute of Science (“Weizmann Institute”) signed a Memorandum of Understanding (MoU). As part of this MoU, scientists from a variety of disciplines from BioNTech and the Weizmann Institute will collaborate in basic and applied research with the aim to better understand various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The joint research will be conducted at BioNTech's newly established mRNA Excellence Center and in Weizmann Institute laboratories.

BioNTech Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in Israel

BioNTech plans to begin clinical trials for its cancer vaccines in the UK this year, according to the company's CEO, Ugur Sahin quoted in the German press. The drug developer, which is best known for its COVID-19 vaccine developed with Pfizer, is deciding which types of cancer it will test its personalised immunotherapies on and where the trials will be conducted.

BioNTech on the verge of UK trials of cancer vaccine - here's our two-minute guide

United Microelectronics

UnitedHealth Group

Undervalued growth stocks are often overlooked by investors, they can offer significant potential for capital appreciation. One way to identify undervalued growth stocks is to look for companies with high revenue and earnings growth, but low price-to-earnings (P/E) ratios.

The 3 Most Undervalued Growth Stocks for Your February Buy List

Novavax

The two companies, known for their vaccines, could see their businesses benefit from a yearly COVID-19 shot.

Better Buy: Novavax or BioNTech Stock?

AbCellera Biologics

Chimerix

iTeos Therapeutics, Inc.

Regeneron Pharmaceuticals

Vir Biotechnology

You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical science.

News for BioNTech SE Stock (BNTX)